Sanofi Pasteur Partners with KaloBios on Novel Biologic for the Prevention and Treatment of Pseudomonas aeruginosa Infections
13-Jan-2010 -
Sanofi Pasteur, the vaccines division of the sanofi-aventis Group, announced an agreement with KaloBios
Pharmaceuticals for the development of a Humaneered™ antibody fragment to both treat and prevent Pseudomonas aeruginosa (Pa) infections.
Under the terms of the agreement, Sanofi Pasteur ...
antibody fragments
clinical trials
cystic fibrosis
+6